RxDoctor Payments Data

David Turney, MD

Family Medicine · Arlington, TXNPI 1538220348

Payments from drug & device makers

$8,723in general payments, 2019–2025

Across 472 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$788
  • AstraZeneca$762
  • Boehringer Ingelheim$639
  • AbbVie$613
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$1,20014%
  • Food & beverage$7,52386%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,723 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$96,004
Medicare patients
308
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide202$224,930
JardianceEmpagliflozin96$126,556
EliquisApixaban153$122,058
TrulicityDulaglutide45$69,783
MounjaroTirzepatide53$60,452
CreonLipase/Protease/Amylase13$41,335
XareltoRivaroxaban42$40,666
JanuviaSitagliptin Phosphate24$36,482
FarxigaDapagliflozin Propanediol38$33,716
TradjentaLinagliptin20$29,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$27,131
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$22,624
RybelsusSemaglutide24$22,293
Janumet XrSitagliptin Phos/Metformin Hcl18$20,367
LinzessLinaclotide22$20,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,296$247,223226 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat, Jentadueto$639$196,205160 claims
Lilly USA, LLCTrulicity, Mounjaro$788$130,23598 claims
PfizerEliquis$553$122,058153 claims
AbbVieCreon, Linzess$613$61,55635 claims
MerckJanuvia, Janumet Xr$289$56,84842 claims
AstraZenecaFarxiga, Breztri Aerosphere$762$56,34066 claims
Johnson & JohnsonXarelto$75$40,66642 claims
GSKTrelegy Ellipta$311$27,13118 claims
Astellas Pharma US IncMyrbetriq$187$7,58913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →